Monopar Therapeutics Inc.
MNPR
$77.19
$1.251.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.11% | 6.53% | 75.97% | -737.66% | 23.96% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.09% | -5.57% | -71.95% | 2,326.37% | -40.46% |
| Change in Net Operating Assets | 156.63% | 102.20% | -207.25% | 12,822.08% | 110.71% |
| Cash from Operations | -94.03% | 80.98% | -183.39% | -86.16% | 35.98% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -279.06% | 464.43% | 97.73% | -1,554.64% | 41,170.83% |
| Cash from Investing | -279.06% | 464.43% | 97.73% | -1,554.64% | 41,170.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,718,476.60% | -69.48% | -99.97% | -- | -100.00% |
| Repurchase of Common Stock | -10,901.71% | -145.31% | -95.96% | -305.45% | -65.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 29,264.02% | -173.81% | -100.21% | 340,323.03% | -66.67% |
| Foreign Exchange rate Adjustments | 115.38% | -2,500.00% | 97.37% | -184.44% | 200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42,188.50% | 96.57% | -115.34% | 39,975.95% | 94.09% |